Report Back From ASCO 2024: What’s the Latest in HR+ MBC?
Today, we’re bringing you a very special episode created in partnership with SHARE Cancer Support. This is an audio version of our webinar “Report Back from ASCO 2024: Latest Updates on Metastatic Breast Cancer (MBC)”.
We're excited to present this report from the 2024 ASCO Annual Meeting, highlighting the latest advancements and research in hormone receptor positive (HR+) metastatic breast cancer. ASCO, the American Society of Clinical Oncology, is a leading organization in the cancer field, and their annual meeting is a crucial event for unveiling groundbreaking research and new treatment options. Attending the congress always amazes us with the sheer number of attendees and the engaging discussions about the newest research and treatments. The poster sessions are particularly eye-opening, showcasing innovation and inspiring hope for future treatments and better side effect management.
In today's episode, you will hear from Dr. Kevin Kalinsky, a medical oncologist and investigator from Emory. We will dive deep into the findings from the DESTINY-Breast06 trial and the postMONARCH trial. We'll explore the implications of these studies, how they could impact treatment strategies, and what this means for us.
Join us as we unpack the key takeaways for HR+ MBC from ASCO 2024.